Loading stock data…
CLLS
$3.70-0.25 (-6.33%)
Market ClosedLast close May 4
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cellectis S.A. in the Healthcare sector is trading at $3.70. The stock is currently 32% below its 52-week high of $5.48, remaining 0.8% above its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why CLLS maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.70
Potential Upside
5%
Whystock Fair Value$3.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$393.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-89.05%
Volume
Today's trading volume
16,230
Recent News
European Equities Traded in the US as American Depositary Receipts Start Week Lower
European equities traded in the US as American depositary receipts kicked off the week lower late Mo
European Penny Stocks To Watch In May 2026
As the European markets navigate through a period of economic uncertainty, with central banks holding rates steady amid geopolitical tensions, investors are keenly watching for opportunities that might emerge in this landscape. One area that continues to intrigue is the realm of penny stocks, which despite their somewhat outdated moniker, remain relevant as a niche investment category. These stocks often represent smaller or newer companies and can offer a blend of affordability and growth...
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week
European equities traded in the US as American depositary receipts were trending marginally higher l
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were lower late Wednesday morning
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
European equities traded in the US as American depositary receipts were rising late Friday morning,